Restem v. JADI Cell: Federal Circuit Affirms US9803176 Unpatentable
Restem, LLC appealed a patentability ruling against its US9803176B2 patent covering methods and compositions for the clinical derivation of allogenic cells and their therapeutic uses. The Federal Circuit affirmed the finding of unpatentability, closing the appeal after 621 days and leaving Restem’s patent claims without enforceable protection.
Federal Circuit seals cancellation of Restem’s allogenic cell patent
Restem, LLC — holder of US9803176B2 claiming methods and compositions for the clinical derivation of allogenic cells and their therapeutic uses — appealed an adverse patentability determination to the United States Court of Appeals for the Federal Circuit. The underlying dispute centered on whether Restem’s patent claims covering allogenic cell-derived therapeutic compositions were valid, with JADI Cell, LLC mounting an invalidity/cancellation action that ultimately succeeded at the tribunal level.
The Federal Circuit issued its order on 4 March 2025, affirming the finding of unpatentability in full. The terse ‘AFFIRMED’ disposition means the appellate court identified no reversible legal or factual error in the lower tribunal’s cancellation of the asserted claims. The basis of termination is recorded as ‘unpatentable,’ confirming the claims are cancelled and no longer enforceable against JADI Cell or any third party.
The 621-day appellate timeline suggests the court engaged substantively with the arguments before reaching its conclusion, though the brief order form is consistent with a straightforward affirmance. The public record does not disclose the specific prior art or claim construction arguments that drove the unpatentability finding, leaving open questions about which claim limitations were most vulnerable. Restem’s route to further review would be a petition for certiorari to the Supreme Court, a path rarely pursued and rarely granted in post-grant patent appeals.
Filing to Unpatentable in 621 days
621 days from filing to Federal Circuit decision — longer than the median PTAB appeal duration of ~450 days
Federal Circuit affirms: what the unpatentability ruling means for both parties
Affirmance means the Federal Circuit found no reversible error below
When the Federal Circuit affirms, it is not issuing a fresh merits ruling — it is confirming that the tribunal below applied the correct legal standards and that its factual findings were supported by substantial evidence. Here, the underlying determination of unpatentability survives intact. Restem’s US9803176B2 claims stand cancelled, and the affirmance closes the last domestic judicial avenue short of Supreme Court review.
No reversible error foundRestem loses enforceable patent rights in allogenic cell derivation
The affirmance extinguishes any enforcement leverage Restem held under US9803176B2. Claims covering methods and compositions for allogenic cell derivation and therapeutic use are cancelled, meaning Restem cannot assert this patent against JADI Cell or any market participant. Restem’s commercial position in the allogenic cell therapy space now depends on any remaining portfolio assets or trade secrets rather than this granted patent.
Patent rights extinguishedJADI Cell secures freedom to operate without US9803176B2 overhead
JADI Cell, LLC has obtained a definitive, court-confirmed ruling that the asserted patent claims are unpatentable. This affirmance provides strong precedential comfort: any future Restem attempt to re-assert equivalent claims faces the cancelled claim history as prior art against prosecution. JADI Cell can now develop and commercialise its allogenic cell technologies without the licensing or design-around costs this patent previously implied.
FTO confirmed by Federal CircuitAllogenic cell therapy space loses one patent barrier — but competitive risk remains
The cancellation of US9803176B2 modestly lowers the patent barrier to entry for allogenic cell therapy developers. However, the outcome should prompt competitors to audit remaining Restem portfolio patents and pending applications claiming similar subject matter. The Federal Circuit affirmance does not preclude continuation patents or divisional claims that may capture overlapping technology, and any such filings warrant close monitoring.
Monitor continuation filingsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Restem, LLC | Company | Biologic cell therapy IP holder — owner of US9803176B2 covering allogenic cell derivationSearch in Eureka ↗ |
| Defendant | JADI CELL, LLC | Company | JADI Cell, LLC — cell therapy company and successful challenger of US9803176B2 validitySearch in Eureka ↗ |
| Plaintiff counsel | Alexander David Walden | Attorney | Counsel for Restem, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Ethan R. Fitzpatrick | Attorney | Counsel for Restem, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Joseph J. Richetti | Attorney | Counsel for Restem, LLCSearch in Eureka ↗ |
| Plaintiff counsel | K. Lee Marshall | Attorney | Counsel for Restem, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Kevin C. Hooper | Attorney | Counsel for Restem, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Bryan Cave Leighton Paisner LLP | Law Firm | Representing Restem, LLCSearch in Eureka ↗ |
| Defendant counsel | Jed H. Hansen | Attorney | Counsel for JADI CELL, LLCSearch in Eureka ↗ |
| Defendant counsel | Mark Bettilyon | Attorney | Counsel for JADI CELL, LLCSearch in Eureka ↗ |
| Defendant law firm | Thorpe North & Western, LLP | Law Firm | Representing JADI CELL, LLCSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s order — ‘THIS CAUSE having been considered, it is ORDERED AND ADJUDGED: AFFIRMED’ — is a summary affirmance form, suggesting the panel found the patentability issues resolved by existing precedent or that the factual record was unambiguous. At the Federal Circuit, affirmance of an unpatentability determination requires the court to find that the tribunal’s claim construction and prior art analysis were legally correct and supported by substantial evidence. The ‘Unpatentable’ basis of termination confirms the claims are cancelled, not merely stayed, leaving Restem with no enforceable rights under this patent.
US9803176B2 — Allogenic cell clinical derivation methods and therapeutic uses
US9803176B2 (application number US13/732204) claims methods and compositions for the clinical derivation of allogenic cells — that is, cells sourced from a donor for therapeutic administration to a genetically non-identical recipient. The patent sits at the intersection of cell biology and regenerative medicine, covering both the derivation process and the resulting therapeutic compositions. Its cancellation by the Federal Circuit removes it from the active patent landscape entirely.
Allogenic cell therapies represent a high-value segment of the broader cell and gene therapy market, where IP protection is intensely contested. A granted patent covering clinical derivation methods and therapeutic compositions would, if valid, create meaningful barriers for competitors developing off-the-shelf allogenic cell products. The cancellation of US9803176B2 is therefore commercially significant for the sector — though companies should audit the broader Restem family and related third-party patents before concluding the FTO landscape is clear.
Should you run an FTO against US9803176B2 and the Restem allogenic cell portfolio?
US9803176B2 is cancelled and no longer poses a direct infringement risk. However, R&D teams and product managers working on allogenic cell derivation, off-the-shelf cell therapies, or related therapeutic compositions should not treat this single cancellation as a clean bill of health. Restem may hold continuation, divisional, or related family patents that claim overlapping subject matter and remain in force. A targeted FTO is still warranted before commercialising products in this space.
PatSnap Eureka’s FTO Search Agent can map the full Restem patent family, identify related granted and pending applications claiming allogenic cell derivation or therapeutic composition subject matter, and flag third-party patents in the same technology cluster. For cell therapy developers, this kind of automated landscape sweep reduces the risk of overlooking closely related claims that survived the cancellation of US9803176B2 and remain enforceable.
Run a freedom-to-operate analysis on US9803176B2 to assess your product’s exposure
Run FTO in Eureka →Federal Circuit appeals affirming unpatentability in cell therapy and biotech
Cases where the Federal Circuit affirmed post-grant unpatentability rulings in allogenic cell therapy, regenerative medicine, and related biologic composition patents.
What this case signals for the cell therapy IP landscape
A Federal Circuit affirmance of unpatentability is a high-stakes outcome — here is what it means for players in the allogenic cell therapy space.
Cancelled claims create prior art risk for continuation prosecution
Cancelled claims from inter partes or post-grant proceedings can inform prior art analyses in related continuation and divisional applications. Restem — or any assignee — prosecuting related applications covering allogenic cell derivation should expect examiners and future challengers to cite the cancellation record. IP teams should map all pending related applications now.
JADI Cell’s freedom to operate is confirmed but not unlimited
The Federal Circuit’s affirmance clears US9803176B2 from JADI Cell’s FTO landscape. However, the allogenic cell therapy space carries broad patent density. JADI Cell and similarly positioned developers should run a comprehensive FTO against related Restem filings and third-party patents covering therapeutic cell compositions before scaling commercialisation.
Restem v JADI — key questions answered
The Federal Circuit affirmed the finding of unpatentability of US9803176B2, a patent owned by Restem, LLC covering methods and compositions for the clinical derivation of allogenic cells and their therapeutic uses. The court’s order, issued 4 March 2025, confirmed the claims are cancelled and the lower tribunal’s ruling contained no reversible error.
US9803176B2 (application number US13/732204) is a United States patent granted to Restem, LLC. It claims methods and compositions for the clinical derivation of allogenic cells — donor-sourced cells intended for therapeutic use in genetically non-identical recipients — and their therapeutic applications. The patent is now cancelled following the Federal Circuit’s affirmance of unpatentability.
When the Federal Circuit affirms, it finds that the tribunal below applied correct legal standards and that factual findings were supported by substantial evidence. No new merits ruling is issued — the lower decision stands. In this case, the affirmance confirms the unpatentability determination and cancellation of Restem’s patent claims, exhausting Restem’s appellate options short of a Supreme Court petition for certiorari.
The Federal Circuit’s affirmance effectively confirms JADI Cell’s freedom to operate with respect to US9803176B2. The cancelled claims can no longer be asserted in infringement proceedings. However, JADI Cell and other allogenic cell therapy developers should conduct a broader FTO against Restem’s remaining portfolio and related third-party patents, as continuation or divisional applications may cover similar subject matter.
Following a Federal Circuit affirmance, the only remaining domestic avenue is a petition for writ of certiorari to the United States Supreme Court. Such petitions are discretionary, granted in fewer than 2% of cases, and particularly rare in post-grant patent validity disputes. The practical effect of the affirmance is that US9803176B2’s cancellation is final for all commercial purposes.
PatSnap Eureka searches patents and litigation data to answer instantly.